| Name: |
|
|
Classification:
|
- Parasympatholytic, anticholinergic
|
|
Mechanism of Action:
|
- Atropine Sulfate is a potent parasympatholytic. It inhibits actions of acetylcholine at postganglionic parasympathetic receptor sites. Blocked vagal effects result in increased heart rate and enhanced AV conduction with limited or no inotropic effects.
|
|
Indications:
|
- Symptomatic bradycardia
- Organophosphate poisoning
- Premedication for succinylcholine in children 16 or less years old
|
|
Contraindications:
|
- Uncorrected tachydysrhythmia
- Hypothermic bradycardia
- 2nd Degree - Type 2 and 3rd Degree Heart block (relative)
|
|
Precautions:
|
- Monitor EKG
- Monitor BP
- Use cautiously in patients taking meds with anticholinergic effects
- Use cautiously in patients taking tricyclic antidepressants
- Use cautiously in patients taking anti Parkinson drugs
- Use cautiously during acute MI, can extend the infarct
- Use very cautiously in patients with glaucoma
|
|
Adverse Effects:
|
- Tachycardia
- Paradoxical bradycardia when pushed too slowly or when used at doses lower than 0.5 mg
- Palpitations
- Dysrhythmias
- Headache
- Dizziness
- Anticholinergic effects: dry mouth/nose/skin photophobia, blurred vision, urinary retention, constipation; nausea and vomiting, flushed hot dry skin, allergic reactions
|
|
Dose:
|
|
|
Adult:
|
- For bradycardia: 1 mg every 3-5 minutes as needed (maximum total dose 3 mg).
- For organophosphate poisoning: 2-4 mg repeated every 20 minutes until muscarinic1 symptoms reverse.
|
| Pediatric: |
- For bradycardia: 0.02 mg/kg (minimum dose 0.1 mg; maximum single dose 0.5 mg). Dose may be repeated once in 3-5 minutes. Maximum total dose for child is 1 mg and 3 mg for an adolescent.
- For organophosphate poisoning 12 years of age and over: 1 mg initially; then repeated and doubling the dose every 5 minutes until muscarinic symptoms reverse.
- For organophosphate poisoning less than 12 years of age: 0.05 mg/kg initially; then repeated and doubling the dose every 5 minutes until muscarinic1 symptoms reverse.
|
| Routes: |
|
| References: |
- TREKK.ca
- Compendium of Pharmaceuticals and Specialties (CPS)
|
Modifié le: lundi 1 décembre 2025, 16:08